Express Scripts Inc. ESRX reported 1Q11 non-GAAP EPS of $0.66 below MS' $0.70 and consensus' $0.69, Morgan Stanley reports.
“Results were driven be a decline in script count, down 5.2 million or 2.7% sequentially and down 0.3% y/y,” Morgan Stanley writes. “Previously announced contract losses including Wal-Mart WMT and Capital BC lowered adjusted scripts by ~6 to 7 million based on our estimates, partially offset by new contract wins, most notably FedEx FDX.”
Express Scripts closed Monday at $55.37.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst RatingsAir Freight & LogisticsCapital BCConsumer Staplesexpress scriptsfedexHealth CareHealth Care ServicesHypermarkets & Super CentersIndustrialsMorgan StanleyWal-Mart
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in